Report of Foreign Issuer (6-k)
October 02 2019 - 6:11AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange
Act of 1934
For the Month of: October 2019
Commission File Number: 001-37847
MOTIF BIO PLC
(Exact name of registrant as specified in its charter)
125 Park Avenue
25th Floor
New York, New York 10017
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ___
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ___
MOTIF BIO PLC
FORM 6-K
Conditional
Placing to raise gross proceeds of £600,000 (US$0.73 million)
On October 2, 2019,
Motif Bio plc (the “Company”) issued a regulatory news service announcement stating that it conditionally raised
£600,000 (US$0.73 million), before expenses by way of a placing (the "Placing") via the issue of 142,857,143 ordinary
shares in the capital of the Company (the "Placing Shares") at an issue price of 0.42 pence per Placing Share (the “Placing
Price”), to provide the Company with additional working capital in order to implement the proposed initiatives as set out
in the Company’s announcement on September 30, 2019 regarding the Proposed Restructuring. A
copy of the regulatory news service announcement is attached herein as Exhibit 99.1.
The information contained in
this report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s registration statements
on Form F-3 (File Nos. 333-222614 and 333-222042), to be a part thereof from the date on which this report is submitted, to the
extent not superseded by documents or reports subsequently filed or furnished.
Exhibits
Signatures
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
MOTIF BIO PLC
|
|
|
|
|
|
|
By:
|
/s/ Graham Lumsden
|
|
|
Name:
|
Graham Lumsden
|
|
|
Title:
|
Chief Executive Officer
|
|
Date: October 2, 2019